Disease · MONDO_0005338

open-angle glaucoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. open-angle glaucoma. Diseases, record MONDO_0005338. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005338

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: open-angle glaucoma; Open Targets
Open Targets ID: MONDO_0005338; Open Targets
Other names: POAG, glaucoma (primary open-angle), glaucoma, open-angle, pigmentary glaucoma, primary open angle glaucoma; Open Targets
Disease Ontology: DOID:1067; Disease Ontology
MeSH: D005902; MeSH
NCI Thesaurus: C34641; NCI Thesaurus
Highest stage of its drugs: Approval, for 22 of its 67 drugs, from DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs67

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LATANOPROST	CHEMBL1051	Small molecule	Approval	DailyMed, EMA Human Drugs and TTD	136	118	112	Drugs and targets
TRAVOPROST	CHEMBL1200799	Small molecule	Approval	DailyMed, EMA Human Drugs, FDA and TTD	95	85	81	Drugs and targets
TIMOLOL	CHEMBL499	Small molecule	Approval	DailyMed and EMA Human Drugs	87	80	74	Drugs and targets
BIMATOPROST	CHEMBL1200963	Small molecule	Approval	DailyMed and EMA Human Drugs	67	59	58	Drugs and targets
TIMOLOL MALEATE	CHEMBL1200870	Small molecule	Approval	DailyMed	80	43	38	Drugs and targets
BRINZOLAMIDE	CHEMBL220491	Small molecule	Approval	DailyMed, EMA Human Drugs and TTD	40	34	33	Drugs and targets
TAFLUPROST	CHEMBL1963683	Small molecule	Approval	DailyMed	23	22	20	Drugs and targets
BRIMONIDINE TARTRATE	CHEMBL1200389	Small molecule	Approval	DailyMed and EMA Human Drugs	35	21	19	Drugs and targets
DORZOLAMIDE	CHEMBL218490	Small molecule	Approval	TTD	21	20	20	Drugs and targets
NETARSUDIL	CHEMBL4594250	Small molecule	Approval	EMA Human Drugs and TTD	18	15	15	Drugs and targets

1 to 10 of 67

See all 67 drugs

Targets45

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Adrenergic receptor beta	11	Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor beta	8	Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist; Beta-2 adrenergic receptor mRNA RNAi inhibitor	Approval	https://conductscience.org/library/genes/154	Drugs and targets
PTGFR	Prostaglandin F2-alpha receptor	7	Prostanoid FP receptor agonist	Approval	https://conductscience.org/library/genes/5737	Drugs and targets
ROCK1	Rho-associated protein kinase	6	Rho-associated protein kinase inhibitor	Approval	https://conductscience.org/library/genes/6093	Drugs and targets
ROCK2	Rho-associated protein kinase	6	Rho-associated protein kinase inhibitor	Approval	https://conductscience.org/library/genes/9475	Drugs and targets
CA2	Carbonic anhydrase 2	4	Carbonic anhydrase II inhibitor	Approval	https://conductscience.org/library/genes/760	Drugs and targets
ADRA2A	Adrenergic receptor alpha	3	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha	3	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha	3	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2908	Drugs and targets

1 to 10 of 45

See all 45 targets

Trials363

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 15 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01632423	A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)		10,337	2012-09-21	Glaucoma, Open-Angle, Ocular Hypertension	BIMATOPROST	Its record names the disease	ClinicalTrials.gov
NCT01646151	A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension		2,580	2014-06-13	Glaucoma, Open-Angle, Ocular Hypertension	BIMATOPROST	Its record names the disease	ClinicalTrials.gov
NCT01853085	A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons		1,830	2015-05-28	Glaucoma, Primary Open Angle, Ocular Hypertension	BIMATOPROST	Its record names the disease	ClinicalTrials.gov
NCT01999348	A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting		1,553	2015-12-09	Glaucoma, Primary Open Angle, Ocular Hypertension	BIMATOPROST, TIMOLOL	Its record names the disease	ClinicalTrials.gov
NCT00950690	Efficacy and Tolerability of Xalatan in Patients		1,289	2009-08-03	Glaucoma, Ocular Hypertension	LATANOPROST	Its record names the disease	ClinicalTrials.gov
NCT01309204	Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension	Phase 3	1,184	2014-04-07	Open-Angle Glaucoma, Ocular Hypertension	BRIMONIDINE, BRINZOLAMIDE	Its record names the disease	ClinicalTrials.gov
NCT01833741	A Study of LUMIGAN® RC in the Clinical Setting	Phase 4	1,137	2013-09-26	Glaucoma, Primary Open Angle, Ocular Hypertension	BIMATOPROST	Its record names the disease	ClinicalTrials.gov
NCT01453855	Travoprost 3-Month Safety and Efficacy Study	Phase 3	1,099	2013-10-18	Open-Angle Glaucoma, Ocular Hypertension	TRAVOPROST	Its record names the disease	ClinicalTrials.gov
NCT01297920	Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%	Phase 3	1,062	2013-07-04	Open-Angle Glaucoma, Ocular Hypertension	BRIMONIDINE TARTRATE, BRINZOLAMIDE	Its record names the disease	ClinicalTrials.gov
NCT01297517	Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%	Phase 3	1,001	2013-05-13	Open-Angle Glaucoma, Ocular Hypertension	BRIMONIDINE, BRIMONIDINE TARTRATE, BRINZOLAMIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 363

See all 363 trials

Comparisons in its trials99

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Brinz/Brim vs Brinz+Brim: serious adverse events	11 of 452	8 of 436	888	NCT01309204	Trial comparisons
Travoprost 0.003% vs TRAVATAN: serious adverse events	5 of 442	7 of 421	863	NCT01453855	Trial comparisons
Travoprost vs Latanoprost: serious adverse events	5 of 363	7 of 363	726	NCT00690794	Trial comparisons
Travoprost vs Latanoprost: serious adverse events	4 of 353	6 of 348	701	NCT00761319	Trial comparisons
PDP-716 vs Brimonidine Tartrate Ophthalmic Solution: deaths from any cause	0 of 337	0 of 341	678	NCT03450629	Trial comparisons
PDP-716 vs Brimonidine Tartrate Ophthalmic Solution: serious adverse events	1 of 337	3 of 341	678	NCT03450629	Trial comparisons
Tafluprost vs Timolol Maleate: serious adverse events	2 of 320	7 of 323	643	NCT01026831	Trial comparisons
Brinzolamide 1% Ophthalmic Suspension vs Azopt 1% Ophthalmic Suspension: deaths from any cause	0 of 320	0 of 318	638	NCT03896633	Trial comparisons
Brinzolamide 1% Ophthalmic Suspension vs Azopt 1% Ophthalmic Suspension: serious adverse events	0 of 320	2 of 318	638	NCT03896633	Trial comparisons
BRIN-20-01 vs Azopt®: deaths from any cause	0 of 297	0 of 300	597	NCT05022004	Trial comparisons

1 to 10 of 99

See all 99 comparisons in its trials

Papers from its trials109

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29194198	RESULT	2	PubMed
27457469	RESULT	1	PubMed
27457257	RESULT	1	PubMed
27292765	RESULT	1	PubMed
27210275	RESULT	1	PubMed
26875002	RESULT	1	PubMed
26563323	RESULT	1	PubMed
25488946	RESULT	1	PubMed
24855336	RESULT	1	PubMed
22918671	RESULT	1	PubMed

1 to 10 of 109

See all 109 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005338

GET https://conductscience.org/api/diseases/v1/MONDO_0005338/drugs?page=2

API reference For AI assistants